Aarti Drugs · NSE: AARTIDRUGS · BSE: 524348
Q4 FY24 results · Jan–Mar 2024
Aarti Drugs reported revenue from operations of ₹619.99 crore (down 16.5% from Q4 FY23) and net profit of ₹47.31 crore (down 15.8% from Q4 FY23) for Q4 FY24 (Jan–Mar 2024), on a consolidated basis.
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 619.99 | 742.41 | −16.5% | 605.94 | +2.3% |
| Other income | 1.08 | 0.87 | +24.1% | 1.67 | −35.3% |
| Total income | 621.07 | 743.28 | −16.4% | 607.61 | +2.2% |
| Profit before tax | 64.18 | 73.28 | −12.4% | 51.55 | +24.5% |
| Net profit for the period | 47.31 | 56.18 | −15.8% | 36.71 | +28.9% |
| Attributable to shareholders of the company | 47.37 | 56.09 | −15.5% | 36.67 | +29.2% |
| EPS, basic (₹) | 5.15 | 6.07 | −15.2% | 3.99 | +29.1% |
| Net margin (%) | 7.6 | 7.6 | 6.1 |
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 559.53 | 696.41 | −19.7% | 538.21 | +4.0% |
| Other income | 1.11 | 0.93 | +19.4% | 1.68 | −33.9% |
| Total income | 560.64 | 697.34 | −19.6% | 539.89 | +3.8% |
| Profit before tax | 49.74 | 69.42 | −28.3% | 42.87 | +16.0% |
| Net profit for the period | 36.14 | 53.17 | −32.0% | 31.62 | +14.3% |
| EPS, basic (₹) | 3.93 | 5.74 | −31.5% | 3.44 | +14.2% |
| Net margin (%) | 6.5 | 7.6 | 5.9 |
Consolidated
- Filed with BSE
- 06 May 2024, 12:00 IST
- Board meeting
- 03 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 06 May 2024, 12:00 IST
- Board meeting
- 03 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE